Recombinant human growth hormone
( DrugBank: - / KEGG DRUG: - )
4 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 77 | Growth hormone secreting pituitary adenoma | 1 |
| 193 | Prader-Willi syndrome | 3 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 265 | Lipodystrophy | 2 |
| 276 | Achondroplasia | 1 |
77. Growth hormone secreting pituitary adenoma
Clinical trials : 351 / Drugs : 241 - (DrugBank : 28) / Drug target genes : 26 - Drug target pathways : 87
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
193. Prader-Willi syndrome
Clinical trials : 128 / Drugs : 94 - (DrugBank : 25) / Drug target genes : 51 - Drug target pathways : 102
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
265. Lipodystrophy
Clinical trials : 127 / Drugs : 137 - (DrugBank : 58) / Drug target genes : 28 - Drug target pathways : 99
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
276. Achondroplasia
Clinical trials : 65 / Drugs : 37 - (DrugBank : 6) / Drug target genes : 5 - Drug target pathways : 29
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|